骨髓体GSK3α缺乏症在动脉样硬化进展期间降低了病变性炎症和新血管化
Sarvatit Patel1, Nisarg Shah1, Brooke D'Mello1,2
1The Thrombosis and Atherosclerosis Research Institute, Hamilton, ON L8L 2X2, Canada.
International journal of molecular sciences
|October 26, 2024
概括
糖原合成酶激酶-3α (GSK3α) 的基因切除减少了小鼠的动脉样硬化,炎症和斑块血管化. 缺乏GSK3α可能为预防动脉样硬化提供了一个新的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 炎症研究 炎症研究
背景情况:
- 心血管风险因素在动脉样硬化病原体中的作用尚不清楚.
- 糖原合成酶激酶-3α (GSK3α) 基因切除先前显示减少了动脉样硬化病变的发展.
- 对于GSK3α和GSK3β在动脉生成中的特定作用,需要进一步研究.
研究的目的:
- 研究GSK3α和/或GSK3β缺乏对动脉样硬化病变炎症和血管化的影响.
- 阐明GSK3在动脉样硬化中的作用背后的分子机制.
主要方法:
- 使用低密度脂蛋白受体缺乏 (Ldlr-/-) 的小鼠进行了10周的高脂肪饮食.
- 在5周大的雌性小鼠中确立了动脉样硬化病变,在15周后收获.
- 标志着动脉样硬化病变,重点关注炎症,斑块体积和血管密度.
主要成果:
- 缺少GSK3α显著降低了斑块体积,病变炎症和大动脉鼻腔血管密度.
- 缺乏GSK3α的小鼠表现出血c反应蛋白 (CRP) 水平的降低.
- 缺乏GSK3β降低了血CRP,但没有影响病变炎症或血管化.
结论:
- 在促进动脉样硬化病变的发展,炎症和血管化的过程中,GSK3α起着至关重要的作用.
- GSK3α代表了开发新型抗atherogenic治疗的潜在治疗目标.
- GSK3β在动脉生成中的作用似乎与GSK3α不同,对病变特征的影响有限.
更多相关视频
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...